Payment overview · 2025
General Payments
$405.07
15 reported records · 8 companies
Healthcare provider profile · identity verified
Robert F. Wolf, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · REYNOLDSBURG, OH · NPI 1992781579
Verified facts
What the public records show
CMS Open Payments records show Robert F. Wolf, M.D. received $405.07 in general payments during 2025 across 15 reported records.
ASAHI INTECC USA, INC. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $134.75 | 33.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.43 | 26.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.64 | 10.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.74 | 7.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.70 | 6.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.24 | 6.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.06 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.51 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.07 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $134.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.43 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.43 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.64 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 98 |
| Omeprazole | Omeprazole | 249 | 76 |
| Losartan Potassium | Losartan Potassium | 237 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 65 |
| Meloxicam | Meloxicam | 187 | 73 |
| Metformin Hcl Er | Metformin Hcl | 183 | 55 |
| Simvastatin | Simvastatin | 180 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 54 |
| Carvedilol | Carvedilol | 158 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 36 |
| Eliquis | Apixaban | 116 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 32 |
| Gabapentin | Gabapentin | 109 | 40 |
| Lisinopril | Lisinopril | 100 | 36 |
| Glimepiride | Glimepiride | 98 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 50 |
| Sertraline Hcl | Sertraline Hcl | 79 | 23 |
| Montelukast Sodium | Montelukast Sodium | 76 | 18 |
| Allopurinol | Allopurinol | 67 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 21 |
| Tramadol Hcl | Tramadol Hcl | 64 | 22 |
| Azithromycin | Azithromycin | 63 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Synthroid | Levothyroxine Sodium | 61 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 18 |
| Pregabalin | Pregabalin | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 45 |
| Spironolactone | Spironolactone | 51 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 20 |
| Furosemide | Furosemide | 49 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 43 |
| Prednisone | Prednisone | 48 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Jardiance | Empagliflozin | 40 | 12 |
| Ketoconazole | Ketoconazole | 40 | 25 |
| Trazodone Hcl | Trazodone Hcl | 39 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 13 |
| Mupirocin | Mupirocin | 36 | 29 |
| Atenolol | Atenolol | 34 | 11 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Metformin Hcl | Metformin Hcl | 34 | 14 |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Klor-Con M20 | Potassium Chloride | 31 | 11 |
| Potassium Chloride | Potassium Chloride | 31 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Famotidine | Famotidine | 29 | 13 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Finasteride | Finasteride | 27 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | 14 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Tobramycin | Tobramycin | 15 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 14 | 14 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.07 · 15 records | ASAHI INTECC USA, INC. | AIRSUPRA, Asahi Peripheral Vascular Wires, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SYNTHROID, TRINTELLIX, UBRELVY, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error